1-6 of 6
Markqayne D. Ray
Close
Sort by
Journal Articles

An Updated Comparison of Clinical Outcomes from 4-Year Follow-up of Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma

John G. Gribben, Paola Ghione, Maria Lia Palomba, Markqayne D Ray, Eve H Limbrick-Oldfield, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A Jacobson, Sattva S. Neelapu, Herve Ghesquieres, Olga Nikolajeva, Jiali Yan, Hailin Wang, Anik R Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 4869.
https://doi.org/10.1182/blood-2023-186842
Published: 2023
Journal Articles

Cost-Effectiveness of Axicabtagene Ciloleucel Versus Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma in the US

Olalekan O. Oluwole, Markqayne D Ray, Richard Zur, Aurelia Little, Cheryl Ferrufino, Brett Doble, Anik R Patel, Pinar Bilir
Journal: Blood
Blood (2023) 142 (Supplement 1): 5082.
https://doi.org/10.1182/blood-2023-186548
Published: 2023
Journal Articles

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Swetha Kambhampati, Hai-Lin Wang, Jiali Yan, Alex F. Herrera, Matthew J. Frank, Leslie L. Popplewell, Nausheen Ahmed, Yi Lin, Frederick L. Locke, Paola Ghione, John G. Gribben, Timothy Best, Christine Fu, Sara Beygi, Markqayne D Ray, John Bian, Zhen-Huan Hu, Fang Sun, Marcelo Pasquini, Caron A. Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 2121.
https://doi.org/10.1182/blood-2023-178629
Published: 2023
Journal Articles

Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies

Frederick L. Locke, Sattva S. Neelapu, Markqayne D. Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R. Patel, Olalekan O. Oluwole
Journal: Blood
Blood (2022) 140 (Supplement 1): 7516–7518.
https://doi.org/10.1182/blood-2022-169812
Published: 2022
Journal Articles

A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Paola Ghione, Maria Lia Palomba, Markqayne D. Ray, Eve H. Limbrick-Oldfield, Jess Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribeiro, Caron A. Jacobson, Sattva S. Neelapu, Herve Ghesquieres, Myrna Nahas, Sara Beygi, Anik R. Patel, John G. Gribben
Journal: Blood
Blood (2022) 140 (Supplement 1): 4676–4677.
https://doi.org/10.1182/blood-2022-170469
Published: 2022
Journal Articles

Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients with Relapsed or Refractory Follicular Lymphoma in the United States

Olalekan O. Oluwole, Markqayne D. Ray, Katherine L. Rosettie, Graeme Ball, Jorge Jacob, Pinar Bilir, Anik R. Patel, Caron A. Jacobson
Journal: Blood
Blood (2022) 140 (Supplement 1): 10822–10824.
https://doi.org/10.1182/blood-2022-163789
Published: 2022